BioCentury
ARTICLE | Finance

Morphic reloads

Why Morphic raised an $80M B round to ramp up development of integrin inhibitors

September 28, 2018 6:16 PM UTC

With Morphic Therapeutic’s second integrin program running ahead of schedule, the company has raised an $80 million series B round to sustain its current development pace.

Existing investor Omega Funds and new investor Novo Holdings A/S led the untranched round, which closed on Sept. 25. New investors Invus and EcoR1 Capital, and existing investors SR One, Pfizer Ventures, AbbVie Ventures, Polaris Partners, computational chemistry company Schrödinger Inc., ShangPharma Innovation Inc., and scientific founder Timothy Springer also participated...